STOCK TITAN
  1. Home
  2. News
  3. BRNS

Barinthus Biotherapeutics plc American Depositary Shares - $BRNS STOCK NEWS

Welcome to our dedicated page for Barinthus Biotherapeutics plc American Depositary Shares news (Ticker: $BRNS), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Barinthus Biotherapeutics plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Barinthus Biotherapeutics plc American Depositary Shares's position in the market.

News
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Rhea-AI Summary

Barinthus Biotherapeutics plc announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer. Dr. Hooftman brings over 25 years of experience in international drug development, specializing in immunology, autoimmunity, hematology, oncology, and infectious diseases. His extensive background includes successful clinical trial programs and senior management positions at leading pharmaceutical companies. Dr. Hooftman's appointment is expected to drive the development of Barinthus Bio's novel T cell immunotherapeutic candidates for chronic infectious diseases, autoimmunity, and cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
none
-
News
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
Rhea-AI Summary
Barinthus Bio announced positive topline data from the Phase 1b/2 APOLLO trial of VTP-200 in persistent high-risk human papillomavirus (HPV) infections. VTP-200 demonstrated positive trends in clearance rates for both high-risk HPV and cervical lesions in groups receiving the highest ChAdOx dose. However, there was no statistically significant improvement compared to the placebo group. The trial met its primary safety endpoint, showing VTP-200 was generally well-tolerated with no severe adverse events. Future development options are being evaluated with ongoing analyses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.38%
Tags
clinical trial
-
News
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
Rhea-AI Summary
Barinthus Biotherapeutics plc (BRNS) reported its 2023 financial results, focusing on clinical developments, operational updates, and upcoming milestones. The company highlighted positive data from HBV and HPV programs, secured future funding, and planned Phase 1 clinical trials. Financially, Barinthus Bio's cash position decreased, revenue dropped significantly, and research and development expenses increased. The net loss for 2023 was $73.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
earnings
News
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
Rhea-AI Summary
Barinthus Biotherapeutics plc (NASDAQ: BRNS) expects to extend its cash runway from Q2 2025 to Q4 2025. The company anticipates multiple data readouts from clinical trials in 2024, focusing on hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection, prostate cancer programs, and the initiation of the first in human study for VTP-1000 in Celiac Disease. As of December 31, 2023, the company's cash and cash equivalents are expected to be $142 million, with approximately 38.6 million ordinary shares issued and outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
New partnership aims to advance vaccine against MERS coronavirus
Rhea-AI Summary
Barinthus Biotherapeutics plc (NASDAQ: BRNS) receives funding from CEPI and the University of Oxford to fast-track the development of MERS vaccine candidate VTP-500
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
partnership
-
News
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Rhea-AI Summary
Barinthus Biotherapeutics plc (NASDAQ: BRNS) presents promising early data from two HBV clinical trials at The Liver Meeting® 2023, showing significant reductions in HBsAg levels with VTP-300 in combination with nivolumab and imdusiran. The trials demonstrate the potential for VTP-300 to be a crucial component in a functional cure regimen for chronic hepatitis B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
clinical trial
News
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
Rhea-AI Summary
Barinthus Biotherapeutics plc (NASDAQ: BRNS) announced its Q3 2023 financial results, revealing a company identity change and upcoming milestones. The company focuses on T cell immunotherapeutic candidates for chronic infectious disease, autoimmunity, and cancer. Recent corporate developments include a name change to reflect its expanded focus. The company also announced upcoming milestones, including interim efficacy data from clinical trials and a regulatory submission application in Australia. Financial highlights include a cash position of $160.3 million, research and development expenses of $15.1 million, and a net loss of $14.1 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
earnings
Stock BRNS logo
Barinthus Biotherapeutics plc American Depositary Shares

Nasdaq:BRNS

BRNS Rankings

#4389 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BRNS Stock Data

88.35M
18.37M
3.69%
47.86%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DIDCOT

About BRNS

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit